News from endo international plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 05, 2022, 16:30 ET ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market...

May 05, 2022, 16:15 ET Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Endo International plc (NASDAQ: ENDP) today announced the upcoming launch of a new clinical study relevant to the use of Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate ...

May 02, 2022, 07:55 ET Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar...

Apr 20, 2022, 17:23 ET Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo

Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals has reversed a trial court judge's order denying a motion for recusal by Endo's wholly-owned subsidiaries...

Apr 12, 2022, 17:00 ET Endo to Announce First-Quarter 2022 Financial Results

Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, ...

Mar 28, 2022, 07:30 ET Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials

Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial. "We ...

Mar 03, 2022, 16:30 ET Endo Launches New Living Our Values Program to Recognize Outstanding Team Members

Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program. "At Endo, we are...

Feb 28, 2022, 16:15 ET ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS

Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance. "Endo's solid ...

Feb 11, 2022, 07:30 ET Endo Comments on Default Judgment on Liability in Tennessee State Court

Endo International plc (NASDAQ: ENDP) today announced that it expects a Tennessee state court to issue an order granting plaintiffs' request for a default judgment on liability against Endo's...

Feb 07, 2022, 07:30 ET Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

First and only manufacturer-prepared, FDA approved vasopressin in a premixed ready-to-use (RTU) format RTU format does not require diluting, or transferring, which may reduce waste and chance of...

Jan 25, 2022, 17:00 ET Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results

Endo International plc (NASDAQ: ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call...

Jan 18, 2022, 07:00 ET Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims

Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. have entered into a statewide...

Jan 17, 2022, 07:30 ET Paladin Labs Announces the Launch of Xydalba® (dalbavancin for injection) in Canada

Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), announced today the launch of Xydalba® (dalbavancin for injection), a 30-minute intravenous (IV) therapy for acute bacterial...

Jan 13, 2022, 07:30 ET Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Pharmacokinetic simulation modeling study predicted more frequent administration with shorter dosing intervals (8 weeks vs. 10 weeks) would reduce serum testosterone fluctuations and elevate...

Jan 11, 2022, 07:00 ET Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development

Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. He will join the...

Jan 10, 2022, 07:30 ET Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold

The campaign features real Dupuytren's contracture (DC) patients and aims to address patient complacency, correct myths and misinformation and highlight the Tabletop Test Dupuytren's contracture is a ...

Jan 04, 2022, 18:25 ET Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic version of Merz's CUVPOSA®...

Jan 04, 2022, 17:00 ET Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference

Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. EST. A live webcast...

Dec 23, 2021, 14:19 ET Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims

Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par...

Dec 23, 2021, 06:00 ET Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada

Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration,...

Dec 15, 2021, 10:23 ET Endo Announces Favorable Final Ruling in California State Court Opioid Trial

Endo International plc (NASDAQ: ENDP) ("Endo") today announced that one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California...

Nov 22, 2021, 10:53 ET Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval ...

Nov 18, 2021, 07:30 ET Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection

Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from ...

Nov 17, 2021, 07:30 ET Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines

Endo International plc (NASDAQ: ENDP) (Endo) today announced that its subsidiary, Par Sterile Products, LLC (Par Sterile), has entered into a cooperative agreement to expand its sterile fill-finish...

Nov 08, 2021, 07:30 ET Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care

Endo International plc (NASDAQ: ENDP) today announced that its Par Sterile Products business will supply VASOSTRICT®, vasopressin injection, USP, vial presentations to healthcare providers through...